These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 21733757)
1. Cladribine as a therapeutic option in multiple sclerosis. Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757 [TBL] [Abstract][Full Text] [Related]
2. Cladribine for multiple sclerosis: review and current status. Sipe JC Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330 [TBL] [Abstract][Full Text] [Related]
3. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. Hecht B Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402 [TBL] [Abstract][Full Text] [Related]
4. New oral drugs for multiple sclerosis. Gasperini C; Ruggieri S Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371 [TBL] [Abstract][Full Text] [Related]
5. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Sipe JC Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859 [TBL] [Abstract][Full Text] [Related]
6. Cladribine: mode of action and implications for treatment of multiple sclerosis. Leist TP; Weissert R Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742 [TBL] [Abstract][Full Text] [Related]
7. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Brousil JA; Roberts RJ; Schlein AL Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095 [TBL] [Abstract][Full Text] [Related]
8. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Warnke C; Wiendl H; Hartung HP; Stüve O; Kieseier BC Drug Des Devel Ther; 2010 Jul; 4():117-26. PubMed ID: 20689698 [TBL] [Abstract][Full Text] [Related]
9. Cladribine. Ortho Biotech Inc. Tortorella C; Rovaris M; Filippi M Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941 [TBL] [Abstract][Full Text] [Related]
11. Emerging oral agents for multiple sclerosis. Fox EJ Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946 [TBL] [Abstract][Full Text] [Related]
12. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518 [TBL] [Abstract][Full Text] [Related]
13. New and emerging disease modifying therapies for multiple sclerosis. Saidha S; Eckstein C; Calabresi PA Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673 [TBL] [Abstract][Full Text] [Related]
14. [Immunosuppressants and multiple sclerosis]. Ruiz-Peña JL; Izquierdo-Ayuso G Rev Neurol; 2002 Aug 16-31; 35(4):373-80. PubMed ID: 12235571 [TBL] [Abstract][Full Text] [Related]
15. [Immunosuppressive medication in multiple sclerosis]. García Merino JA Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298 [TBL] [Abstract][Full Text] [Related]
16. Development of oral cladribine for the treatment of multiple sclerosis. Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304 [TBL] [Abstract][Full Text] [Related]
17. Development of cladribine treatment in multiple sclerosis. Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414 [TBL] [Abstract][Full Text] [Related]
18. Treatment options for multiple sclerosis: current and emerging therapies. Gawronski KM; Rainka MM; Patel MJ; Gengo FM Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847 [TBL] [Abstract][Full Text] [Related]
19. Principles of a new treatment algorithm in multiple sclerosis. Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441 [TBL] [Abstract][Full Text] [Related]